Indivior Pharmaceuticals Inc
INDV scores 61.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -10.7 points significantly impact the ranking. Without these adjustments, INDV would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| INDV | 61.0 | 25.5 | 8.7% | 14.1% | $4.4B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| ASND | 78.2 | 16.6 | 98.0% | -31.7% | $13.8B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.4 | 41.9 | 161.5% | -3292.7% | — |
Indivior Pharmaceuticals Inc is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in North Chesterfield, VA.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $314M | $302M | $266M | $299M |
| Gross Profit | $230M | $250M | $222M | $276M |
| Operating Income | $43M | $72M | $66M | $96M |
| Net Income | $42M | $18M | $47M | $59M |
| EPS (Diluted) | $0.33 | $0.14 | $0.38 | $0.45 |
| Gross Margin | 73.2% | 82.8% | 83.5% | 92.3% |
| Operating Margin | 13.7% | 23.8% | 24.8% | 32.1% |
| Net Margin | 13.4% | 6.0% | 17.7% | 19.7% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $8.00 | $18.05 | 77.2% | Wide |
| 2022 | $3.13 | $22.00 | 150.2% | Wide |
| 2023 | $14.38 | $26.50 | 59.3% | Wide |
| 2024 | $7.33 | $23.22 | 104% | Wide |
| 2025 | $7.62 | $38.00 | 133.2% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.